Zenyaku Kogyo Co., Ltd. and Chugai Pharmaceutical Co., Ltd. announced that Zenyaku obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for an anti-CD20 monoclonal antibody Rituxan injection 100 mg and 500 mg [generic: rituximab (genetical recombination)] for additional indications of refractory pemphigus vulgaris and pemphigus foliaceus. Rituxan is co-marketed by the two companies in Japan.
Zenyaku Kogyo and Chugai Pharmaceutical announced that Zenyaku obtained approval from the Ministry of Health, Labour and Welfare (MHLW), for an anti-CD20 monoclonal antibody, Rituxan injection 100 mg and 500 mg [generic name: rituximab (genetical recombination)] for an additional indication of systemic sclerosis (SSc). Rituxan is co-marketed by the two companies in Japan.